Saturday 17 October 2026
Export SKIN’s income statement to Excel — free account
SkinHealth Systems Inc.
SKIN Consumer Defensive Household & Personal Products
SkinHealth Systems Inc.’s revenue for fiscal 2025 (year ended December 2025) was $300.8 million, down 10.0% from fiscal 2024. In the quarter to June 2026, revenue fell 7.77%, EPS fell 112.5%, free cash flow fell 81.9% and total debt fell 4.93%, each against the same quarter a year earlier.
10.56
2.04
−16.19%
Follow SKIN
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | 3 | 4 | 8 | 6 |
P/E ratio |
— | 0.00 | 0.00 | 0.00 | 28.90 | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | 0.00 | 0.00 | 9.49 | 3.72 | 1.02 | 0.59 | 0.58 |
Altman Z-Score |
— | — | 1.08 | 2.15 | 1.57 | 0.28 | 0.03 | (0.45) |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 21.08 | 5.43 |
Altman Z″-Score (non-manufacturers) |
— | — | (0.45) | 3.98 | 3.46 | 1.56 | 0.92 | (1.89) |
Beneish M-Score |
— | — | — | (3.05) | (1.31) | (2.94) | (3.35) | (3.05) |
P/Operating CF |
— | (978.70) | (594.72) | 752.39 | (252.26) | (78.70) | 11.95 | 11.56 |
P/B ratio |
— | 16,325.50 | 130.07 | 8.16 | 8.14 | 6.85 | 3.80 | 2.88 |
Price to Tangible BV |
— | 16,325.50 | 0.00 | 20.12 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
— | 0.00 | 0.00 | 8.84 | 4.19 | 1.58 | 1.15 | 1.02 |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | 1,216.01 | 0.00 | 0.00 | 37.57 |
EV/Operating CF |
— | 0.00 | (75.84) | (81.07) | (14.38) | 28.84 | 23.80 | 8.20 |
EV/FCF |
— | 0.00 | (75.84) | (52.28) | (12.22) | (64.29) | 41.12 | 9.51 |
Quick Ratio |
— | — | 1.06 | 12.47 | 9.01 | 5.03 | 5.85 | 1.37 |
Current Ratio |
— | — | 1.91 | 13.09 | 10.92 | 6.07 | 7.00 | 1.66 |
Net Debt/EBITDA |
— | 0.00 | (176.97) | 9.36 | 137.15 | (2.34) | (5.92) | 16.10 |
Debt/Assets |
0.00% | 0.00% | 97.17% | 60.22% | 73.89% | 79.47% | 80.53% | 72.91% |
Debt/Equity |
— | 0.00 | (7.23) | 2.43 | 4.44 | 12.43 | 10.66 | 5.97 |
Asset Turnover |
— | 0.00 | 1.07 | 0.36 | 0.33 | 0.41 | 0.41 | 0.51 |
Operating CF/Net income |
— | (1.05) | 0.43 | 0.07 | (2.41) | (0.22) | (0.55) | (3.94) |
Capex/Depreciation |
— | (0.69) | (0.24) | (0.71) | (0.70) | (0.81) | (0.18) | (0.18) |
Interest Coverage |
— | 0.79 | (0.81) | (3.39) | (1.93) | (9.59) | (6.51) | (1.08) |
| — | 0.00% | (21.45%) | (278.16%) | 18.84% | (88.42%) | (52.34%) | (16.87%) | |
| — | 0.00% | (26.19%) | (52.55%) | 3.98% | (10.36%) | (3.60%) | (1.61%) | |
ROIC |
— | 0.00% | (6.06%) | (18.58%) | (4.75%) | (29.78%) | (18.11%) | (6.74%) |
Return on Tangible Assets |
— | 0.00% | (78.10%) | (40.27%) | 6.06% | (16.76%) | (7.01%) | (7.57%) |
Average Days of Receivables |
— | 0.00 | 71.06 | 72.17 | 77.59 | 50.47 | 31.08 | 28.44 |
Research and Development Expense of Revenue |
— | 2.77% | 2.86% | 3.15% | 2.31% | 2.54% | 1.88% | 1.87% |
Selling, General and Administrative Expense of Revenue |
— | 53.08% | 67.99% | 80.85% | 72.75% | 69.33% | 72.92% | 70.33% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.67 | 0.15 | 0.17 | 0.20 | 0.25 | 0.32 |
Share Based Compensation of Revenue |
— | 0.06% | 0.30% | 4.77% | 7.79% | 5.66% | 7.99% | 4.93% |
Graham Net Nets |
— | 0.00 | (0.02) | 0.03 | (0.04) | (0.42) | (0.80) | (0.74) |
Graham Number |
— | 0.00 | 0.00 | 0.00 | 2.85 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | (0.18%) | (0.18%) | (13.92%) | 3.46% | (24.92%) | (14.71%) | (5.04%) |
Free Cash Flow Yield |
— | 0.00% | (1.75%) | (1.78%) | (9.22%) | (2.40%) | 4.74% | 18.40% |
Revenue per Share |
— | 5.18 | 3.47 | 2.55 | 2.48 | 3.02 | 2.70 | 2.38 |
Operating CF per Share |
— | 0.05 | (0.36) | (0.28) | (0.72) | 0.17 | 0.13 | 0.30 |
Capex per Share |
— | (0.32) | (0.11) | (0.15) | (0.13) | (0.24) | (0.05) | (0.04) |
Free Cash Flow per Share |
— | (0.27) | (0.47) | (0.43) | (0.85) | (0.07) | 0.08 | 0.26 |
Cash per Share |
— | 0.00 | 0.28 | 8.83 | 3.85 | 3.97 | 2.99 | 1.84 |
Shareholders Equity per Share |
— | 0.00 | (0.87) | 2.96 | 1.13 | 0.45 | 0.42 | 0.48 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 0.00 | (0.87) | 2.96 | 1.13 | 0.45 | 0.42 | 0.48 |
Free Cash Flow |
— | (8.69) | (16.25) | (43.98) | (125.47) | (9.76) | 9.34 | 32.32 |
Working Capital |
— | — | 28.17 | 924.46 | 711.56 | 583.24 | 408.97 | 123.24 |
Capital Expenditures |
— | (10.42) | (3.82) | (15.62) | (18.87) | (31.51) | (6.79) | (5.16) |
Net Current Asset Value |
— | 0.00 | (193.70) | 84.38 | (52.75) | (171.47) | (156.76) | (129.23) |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | 0.06 | 0.03 | 0.06 | 0.05 | 0.08 | 0.02 | 0.02 |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||
Depreciation/Fixed assets |
— | 0.00 | 1.74 | 1.36 | 1.49 | 2.73 | 6.19 | 11.42 |
Cash ROIC |
— | 0.00% | (8.29%) | (2.27%) | (8.50%) | (0.74%) | 0.96% | 4.91% |
Accounts Receivable Turnover |
— | 0.00 | 3.22 | 6.97 | 5.66 | 5.99 | 8.01 | 11.59 |
Accounts Payable Turnover |
— | 0.00 | 2.21 | 3.43 | 4.07 | 6.63 | 4.56 | 5.56 |
Inventory Turnover |
— | 0.00 | 1.79 | 2.79 | 1.62 | 2.42 | 1.89 | 1.78 |
Average Days of Payables |
— | 0.00 | 130.02 | 130.02 | 88.73 | 67.28 | 52.69 | 54.64 |
Days of Inventory on Hand |
— | 0.00 | 163.20 | 157.82 | 341.81 | 137.24 | 165.96 | 167.82 |
Average Receivables |
— | — | 37.00 | 37.31 | 64.60 | 66.40 | 41.75 | 25.95 |
Average Payables |
— | — | 23.50 | 23.77 | 28.76 | 36.62 | 33.35 | 18.79 |
Average Inventory |
— | — | 29.00 | 29.23 | 72.46 | 100.49 | 80.22 | 58.56 |
Average Assets |
— | 0.00 | 111.42 | 720.82 | 1,110.94 | 966.10 | 807.40 | 592.74 |
Average Common Equity |
— | — | 136.00 | 136.17 | 234.68 | 113.22 | 55.60 | 56.43 |
Columns are period end dates